All Pharma News
NCC, PeptiDream: 64Cu-PD-32766 First Dosing In Renal Cell Carcinoma

NCC, PeptiDream: 64Cu-PD-32766 First Dosing In Renal Cell Carcinoma
BUSINESSWIRE
04 Jun 2024
Share Share
PeptiDream Announces Expansion of Peptide Discovery Collaboration with Novartis

PeptiDream Announces Expansion of Peptide Discovery Collaboration with Novartis
BUSINESSWIRE
30 Apr 2024
Share Share
Novartis pays PeptiDream $180M as radiopharma big bang continues

Novartis pays PeptiDream $180M as radiopharma big bang continues
Nick Paul Taylor FIERCE BIOTECH
29 Apr 2024
Share Share
PeptiDream Announces Collaboration and License Agreement with Genentech

PeptiDream Announces Collaboration and License Agreement with Genentech
BUSINESSWIRE
20 Sep 2023
Share Share
PeptiDream Announces Nomination of Second Peptide Radiopharmaceutical Therapeutic Development Candidate

PeptiDream Announces Nomination of Second Peptide Radiopharmaceutical Therapeutic Development Candidate
BUSINESSWIRE
22 Mar 2023
Share Share
PeptiDream Announces New Research and Collaboration Agreement with Lilly

PeptiDream Announces New Research and Collaboration Agreement with Lilly
BUSINESSWIRE
28 Dec 2022
Share Share
PeptiDream and RayzeBio Expand Alliance on Peptide-Radiotherapeutics

PeptiDream and RayzeBio Expand Alliance on Peptide-Radiotherapeutics
PRESS RELEASE
09 Aug 2022
Share Share
PeptiGrowth Inc. is Launching A Novel Synthetic Peptide BMP4,7 inhibitor (Noggin-like peptide)

PeptiGrowth Inc. is Launching A Novel Synthetic Peptide BMP4,7 inhibitor (Noggin-like peptide)
PRESS RELEASE
30 Jun 2022
Share Share
PeptiAid Co., Ltd. Announces the Progress of Clinical Research on the New Coronavirus Infection Drug PA-001

PeptiAid Co., Ltd. Announces the Progress of Clinical Research on the New Coronavirus Infection Drug PA-001
CMOCRO
17 Jun 2022
Share Share
BIOHAVEN ENROLLS PHASE 1A/1B CLINICAL TRIAL OF BHV-1100, LEAD ASSET ITS ARM™

BIOHAVEN ENROLLS PHASE 1A/1B CLINICAL TRIAL OF BHV-1100, LEAD ASSET ITS ARM™
BIOHAVENPHARMA
27 Oct 2021
Share Share